Considering only the PCa samples under this prognostic classification for the analysis, a considerable number of the samples are categorised as low-/intermediate- risk tumours: [31% correspond to stage I, 13.8% stage IIA, 31% stage IIB (3 individuals of this group of patients presented PSA 10–17 ng/mL when diagnosed)], whereas near a quarter of the samples are classified as high-risk tumours: 13.8% stage intermediate-high risk IIC and 10.3% stage high risk-advanced IIIB [two of the individuals presented PSA > 10 ng/mL (12.5 ng/mL and 17.7 ng/mL) at the time of diagnosis]. This evidence concerns the gene KLK3 and neoplasm.